• 검색 결과가 없습니다.

Issues on Estimated Pulmonary Artery Pressure in Liver Transplant Candidates

N/A
N/A
Protected

Academic year: 2021

Share "Issues on Estimated Pulmonary Artery Pressure in Liver Transplant Candidates"

Copied!
2
0
0

로드 중.... (전체 텍스트 보기)

전체 글

(1)

61 https://e-jcvi.org

Estimating pulmonary artery systolic pressure (PASP) by Doppler echocardiography has been widely used in clinical practice since it is known to be correlated with invasively measured PASP, easy to perform, and stratifies a clinical outcome in various cardiovascular disease.1-4) Importantly, PASP changes according to left ventricular filling pressure, stroke volume and pulmonary vascular resistance.1)2) Therefore, it has dynamic nature based on the loading conditions at the time of Doppler evaluation or exercise.

In patients with advanced chronic liver disease, who are candidates for liver transplantation, pulmonary vascular disorders including portopulmonary hypertension (PoPHT) are common.5) Because PoPHT has prognostic significance, echocardiography is mandatory in the evaluation of patients with advanced liver disease prior to liver transplant even when the patients are asymptomatic.6) Although right heart catheterization is the gold standard for diagnosis of pulmonary hypertension, it has been used in selected cases to confirm or grade pulmonary hypertension. Particularly, patients with advanced liver disease commonly have low platelet counts and impaired immune system therefore are prone to have procedure related complications including hematoma or infection. Therefore, understanding of diagnostic performance of Doppler estimated PASP for diagnosing pulmonary hypertension is crucial.

In this issue of the Journal, Habash et al.7) report the results of their study of 31 patients being evaluated for liver transplant compared with control subjects without liver disease.

They analysed Doppler-estimated PASP and invasive PASP directly measured by right heart catheterization. They demonstrated that the correlation between two parameters was only modest and an estimated PASP > 47 mmHg was only 59% sensitive and 78% specific in diagnosing pulmonary arterial hypertension defined as mean pulmonary arterial pressure >

25 mmHg in patients with advanced liver disease, while estimated PASP > 43 mmHg was 91%

sensitive and 100% specific in patients without liver disease.

Although this paper contains of the accuracy and cut-off values of a very important hemodynamic parameter in diagnosing pulmonary hypertension, some limitations should be keep in mind before interpreting the results and applying the conclusion to our practice.

First, patients with advance liver disease may change their intracardiac volume status J Cardiovasc Imaging. 2018 Jun;26(2):61-62

https://doi.org/10.4250/jcvi.2018.26.e7 pISSN 2586-7210·eISSN 2586-7296

Editorial

Received: May 27, 2018 Address for Correspondence:

Chi Young Shim, MD, PhD Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea.

E-mail: [email protected]

Copyright © 2018 Korean Society of Echocardiography

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://

creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ORCID iDs Chi Young Shim

https://orcid.org/0000-0002-6136-0136 Conflict of Interest

The authors have no financial conflicts of interest.

Chi Young Shim , MD, PhD

Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea

Issues on Estimated Pulmonary

Artery Pressure in Liver Transplant Candidates

See the article “Correlation between Echocardiographic Pulmonary Artery Pressure Estimates and Right Heart Catheterization Measurement in Liver Transplant Candidates” in volume 26 on page 75.

(2)

according to presence of hypoalbuminemia, ascites, and/or the use of diuretics for 3 months.

Since this study was retrospectively performed, the non-invasive hemodynamic results may influence the patient's treatment including medications. Second, the recognition of PoPHT in patients with advanced liver disease requires high clinical suspicion because symptoms may not be overt. Therefore, the most important role of non-invasive assessment of PASP is not on the accuracy and specificity but on sensitivity as a screening tool for pulmonary hypertension. In the present study, the sensitivity of ePASP > 47 mmHg was only 59%. Third, the differences in baseline characteristics between two groups seems to be prominent. The control group showed a higher prevalence of co-morbidities and most importantly had a higher PASP reflecting a more advanced status of pulmonary hypertension. Although this original investigation has a few intrinsic limitations, a relatively poor diagnostic performance of ePASP for pulmonary hypertension in candidates for liver transplantation may provide us scientific stimuli for the simultaneous hemodynamic comparisons in patients with advanced liver disease.

REFERENCES

1. Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:40S-47S.

PUBMED | CROSSREF

2. Shim CY, Kim SA, Choi D, et al. Clinical outcomes of exercise-induced pulmonary hypertension in subjects with preserved left ventricular ejection fraction: implication of an increase in left ventricular filling pressure during exercise. Heart 2011;97:1417-24.

PUBMED | CROSSREF

3. Yoo SJ, Park JH, Park Y, et al. Prevalence of pulmonary arterial hypertension in Korean adult patients with systemic sclerosis: result of a pilot echocardiographic screening study. J Cardiovasc Ultrasound 2016;24:312-6.

PUBMED | CROSSREF

4. Seo YH, Choi HJ. Clinical utility of echocardiography for early and late pulmonary hypertension in preterm infants: relation with bronchopulmonary dysplasia. J Cardiovasc Ultrasound 2017;25:124-30.

PUBMED | CROSSREF

5. Krowka MJ, Mandell MS, Ramsay MA, et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl 2004;10:174-82.

PUBMED | CROSSREF

6. Bozbas SS, Bozbas H. Portopulmonary hypertension in liver transplant candidates. World J Gastroenterol 2016;22:2024-9.

PUBMED | CROSSREF

7. Habash F, Gurram P, Almomani A, et al. Correlation between echocardiographic pulmonary artery pressure estimates and right heart catheterization measurement in liver transplant candidates. J Cardiovasc Imaging 2018;26:75-84.

CROSSREF

62 https://e-jcvi.org https://doi.org/10.4250/jcvi.2018.26.e7

Pulmonary Artery Pressure in Liver Disease

참조

관련 문서

The locations of aneurysms were middle cerebral artery in 15 patients, cerebral artery in 15 patients, cerebral artery in 15 patients, cerebral artery in

Serum uric acid levels and risk for vascular disease in patients with metabolic syndrome... Prevalence if the metabolic syndrome in a Turkish

(Method) Among 102 patients with metastatic liver carcinoma due to colorectal cancer who were treated at Chosun University Hospital from January 2003 to

The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new‑onset type 2

Among the various pulmonary manifestations, interstitial lung disease (ILD) is known to be associated with substantial morbidity and mortality rates in RA patients.. As RA-ILD

1 reported the usefulness of the metabolic score for insulin resistance (METS-IR) in the screening and prediction of non- alcoholic fatty liver disease (NAFLD) in middle-aged

MAFLD, metabolic dysfunction-associated fatty liver disease; NAFLD, nonalcoholic fatty liver disease; CVD, cardiovascular disease; CI, confidence interval; Model 1,

cACLD = compensated advanced chronic liver disease, dACLD = decompensated advanced chronic liver disease, LS = liver stiffness, LS-SIR = liver-to-spleen signal intensity